Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting Dec 09, 2019 10:00am EST
Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference Nov 26, 2019 4:00pm EST
Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress Nov 07, 2019 7:30am EST
Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting Nov 06, 2019 9:01am EST
Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019 Oct 30, 2019 4:05pm EDT
Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019 Sep 09, 2019 8:00am EDT
Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress Aug 08, 2019 7:30am EDT
Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019 Aug 01, 2019 4:00pm EDT
